Brugada syndrome

What is Brugada syndrome? 

Brugada syndrome is an inherited heart disorder that affects the electrical activity of the heart. This electrical activity is essential for the proper functioning of the heart, as it controls the rhythm and strength of the heartbeats. It affects between 1 and 5 out of every 10,000 people worldwide, mainly young and middle-aged adults, and is more common in men than in women.  

In Brugada syndrome, abnormalities in the ion channels (small gates that regulate the flow of ions into and out of heart cells) disrupt the normal flow of electricity. This can trigger rapid and dangerous abnormal heart rhythms, especially in the ventricles, the lower chambers of the heart. Rhythms such as ventricular fibrillation can cause fainting or even sudden death.  

Brugada syndrome often presents no symptoms, so many people are unaware that they have it until they experience a serious event. This condition significantly impacts quality of life due to the constant risk of potentially life-threatening complications. 

Although Brugada syndrome can be a serious disease, it is not always the case, and proper diagnosis and treatment can help prevent potentially life-threatening complications. 

It is important to note that the severity and presentation of symptoms can vary considerably from one individual to another, even among members of the same family. 

Classification of Brugada syndrome 

Brugada syndrome is classified according to the patterns observed on the electrocardiogram (ECG), a test that records the electrical activity of the heart. In Brugada syndrome, these electrical waves can have abnormal shapes: 

• Type 1: it presents a tent-shaped ST-segment elevation in the right ECG leads (V1 and V2). This is the definitive diagnostic pattern. 
• Type 2: it shows a saddle-shaped ST-segment elevation. It may be suggestive of Brugada syndrome, but requires further testing. 
• Type 3: it presents a smaller ST-segment elevation. It is also suggestive, but it needs further investigation. Causes of Brugada syndrome 

Causes of Brugada syndrome 

Brugada syndrome is primarily caused by genetic mutations that affect the ion channels of the heart. These channels are proteins that control the flow of ions such as sodium, potassium, and calcium across cell membranes. This flow is essential for generating and regulating the electrical impulses that control the heartbeat. 

Mutations in the genes that encode these channels can alter their function, causing the electrical abnormalities characteristic of Brugada syndrome. The most commonly affected gene is SCN5A, which encodes the alpha subunit of the cardiac sodium channel Nav1.5. 

Do you need a second medical opinion or more specific help?

Tell us what you need, write your details and one of our specialists will call you as soon as possible to help you.

We will call you

Complications of Brugada syndrome 

The most serious complication of Brugada syndrome is sudden cardiac death. This can occur without prior warning, even in people who have not previously experienced symptoms.  

The true incidence of death from Brugada syndrome is not precisely known, but it may account for 3% to 20% of all sudden deaths in patients with structurally normal hearts. Sudden deaths tend to occur most frequently between the ages of 20 and 40. It is recommended that the patient, family, and close contacts know the cardiopulmonary resuscitation (CPR) procedure. 

Other complications include syncope and palpitations. It is crucial to seek medical attention if Brugada syndrome is suspected to minimize the risk of these complications. 

Diagnosis of Brugada syndrome 

The diagnosis of Brugada syndrome is based primarily on electrocardiogram (ECG) findings. An ECG records the heart’s electrical activity and may reveal the characteristic patterns of Brugada syndrome, such as ST-segment elevation in the precordial leads. Sometimes, the ECG pattern may be intermittent or subtle, so additional tests may be used to confirm the diagnosis. 

• Drug provocation test: if the initial ECG is normal or inconclusive, a drug that blocks sodium channels (such as ajmaline, flecainide, or procainamide) may be administered to see if it triggers the characteristic ECG pattern of Brugada syndrome. This test must be performed in a hospital setting under the supervision of a cardiologist, as it can cause arrhythmias. 

• Electrophysiological study: in some cases, an electrophysiological study can be performed. This procedure involves inserting thin catheters into the heart through a vein to record the heart’s electrical activity in greater detail and assess the risk of arrhythmias. 

• Genetic testing: they can identify mutations in genes associated with Brugada syndrome, although not all people with the syndrome have an identifiable genetic mutation. These tests can be useful for family screening. 

• Differential diagnosis: Brugada syndrome can mimic other heart conditions that also cause syncope, so it is essential to make an accurate differential diagnosis. Other tests such as magnetic resonance imaging or computed tomography can be carried out for this purpose. 

Treatment of Brugada syndrome 

The main goal of Brugada syndrome treatment is to prevent sudden cardiac death. The choice of treatment depends on each patient’s individual risk of developing serious arrhythmias. 

• Lifestyle changes: avoiding known triggers, such as certain medications, excessive alcohol consumption, and high fevers, is crucial for people with Brugada syndrome. 

• Implantable Cardioverter-Defibrillator (ICD): for people at high risk of sudden cardiac death, implantation of an ICD is the most effective treatment. An ICD is a small device that is implanted in the heart and continuously monitors the heart rhythm. If it detects a life-threatening arrhythmia, it sends an electrical shock to the heart to restore a normal rhythm. Although implanting an ICD is a necessary treatment in some cases, it also carries the risk of device-related complications. 

• Medications: in some cases, antiarrhythmic medications can be used to reduce the risk of arrhythmias. However, medications are not as effective as an ICD in preventing sudden cardiac death. 

• Radiofrequency ablation (RFA): it is a procedure that uses radiofrequency energy to destroy small areas of heart tissue that cause arrhythmias. It may be an option for some people with Brugada syndrome who experience arrhythmias despite medication. However, more research is needed to determine the long-term effectiveness of ablation in this syndrome. 

Optimal management may require a multidisciplinary approach involving cardiologists, electrophysiologists, and geneticists. 

Remember that this article is for informational purposes only and does not replace professional medical advice. If you suspect you have complications and symptoms related to Brugada syndrome, consult a specialist to obtain an accurate diagnosis and an appropriate treatment plan tailored to your needs.